ProCE Banner Activity

Neoadjuvant and Adjuvant Therapy Strategies for Patients With Resectable Pancreatic Cancer

Multimedia
This brief virtual presentation provides expert insights into the current optimal use of neoadjuvant and adjuvant therapy strategies for patients with resectable or borderline resectable pancreatic cancer.

Released: March 01, 2021

Expiration: February 28, 2022

Share

Faculty

Paul E. Oberstein

Paul E. Oberstein, MD

Assistant Professor of Medicine
Division of Hematology/Medical Oncology
NYU Langone Health
Director, GI Medical Oncology
NYU Perlmutter Comprehensive Cancer Center
NYU Langone Healthy
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Ipsen Biopharmaceuticals Inc

Learning Objectives

  • Discuss the available data and ongoing trials investigating neoadjuvant and adjuvant therapy settings

Program Director Disclosure

Program Director

Paul E. Oberstein, MD

Assistant Professor of Medicine
Division of Hematology/Medical Oncology
NYU Langone Health
Director, GI Medical Oncology
NYU Perlmutter Comprehensive Cancer Center
NYU Langone Healthy
New York, New York

Paul E. Oberstein, MD, has disclosed that he has received consulting fees from Genentech, Ipsen, Merck, and Rubius.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.